Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...

NICE has proposed age-based CA125 thresholds to improve early ovarian cancer detection while reducing unnecessary scans in ...

The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...

Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...

Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readinessCompany on track to initiate ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...

Hormone therapy, also known as endocrine therapy, is a type of treatment your doctor may recommend as part of treatment for certain types of ovarian cancer, but not right away. Surgery is the first ...

InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology ...

A sponge-like gold nanoparticle platform could deliver faster, more accurate, and less invasive ovarian cancer diagnostics.